← Ablatotech Vitals
Nephrology EvidenceDigest

Emerging Evidence on the Use of Anti-NGF (Nerve Growth Factor) Therapies for Pain Management in Chronic Kidney Disease

Nephrology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
November 17, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Anti-nerve growth factor (anti-NGF) therapies represent a promising new approach for managing chronic pain, including in patients with chronic kidney disease (CKD), where conventional analgesics like NSAIDs pose significant risks. Early clinical evidence, including veterinary studies in CKD-affected felines, suggests that anti-NGF monoclonal antibodies can reduce pain severity without compromising renal function. However, human data remain limited, and safety concerns related to joint health and long-term effects warrant cautious interpretation. Anti-NGF agents may offer an alternative for CKD patients with refractory musculoskeletal pain, but further clinical trials are needed to establish efficacy, optimal dosing, and safety profiles in this population.

Clinical bottom line

Anti-nerve growth factor (anti-NGF) therapies represent a promising new approach for managing chronic pain, including in patients with chronic kidney disease (CKD), where conventional analgesics like NSAIDs pose significant risks. Early clinical evidence, including veterinary studies in CKD-affected felines, suggests that anti-NGF monoclonal antibodies can reduce pain severity without compromising renal function. However, human data remain limited, and safety concerns related to joint health and long-term effects warrant cautious interpretation. Anti-NGF agents may offer an alternative for CKD patients with refractory musculoskeletal pain, but further clinical trials are needed to establish efficacy, optimal dosing, and safety profiles in this population.

What the evidence shows

Nerve growth factor (NGF) is a neurotrophin critically involved in the sensitization and transmission of pain signals, particularly in chronic musculoskeletal conditions (Mizumura et al., 2022; Cohen et al., 2016). Anti-NGF monoclonal antibodies target this pathway, reducing pain by inhibiting NGF’s interaction with its receptors on nociceptive neurons (Norman et al., 2016; Schmelz et al., 2017). This mechanism differs fundamentally from NSAIDs and opioids, potentially avoiding their renal and systemic toxicities.

Clinical efficacy of anti-NGF therapies has been demonstrated in osteoarthritis and other chronic pain syndromes, with significant pain reduction and improved function reported in multiple trials (Bannwarth et al., 2014; Cohen et al., 2016). Notably, a recent veterinary study evaluated anti-NGF monoclonal antibody treatment in felines with osteoarthritis concurrent with CKD, showing meaningful analgesic benefit without worsening kidney function or adverse renal effects (Nutthawat et al., 2025). This study provides a relevant translational model given the similar challenges of pain management in CKD.

Mechanistically, anti-NGF agents act upstream of inflammatory mediators targeted by NSAIDs, offering a novel analgesic strategy that may be safer for CKD patients who are at risk of NSAID-induced nephrotoxicity (Schmelz et al., 2017). The potential to reduce opioid reliance is also clinically important given the risks of opioid use in CKD.

Caveats and uncertainty

Despite encouraging preclinical and veterinary data, robust human clinical trial evidence specifically in CKD populations is lacking. Most anti-NGF trials to date have excluded patients with significant renal impairment, limiting direct applicability. Safety concerns remain, particularly regarding the risk of rapidly progressive osteoarthritis and joint destruction observed in some patients receiving anti-NGF therapy (Bannwarth et al., 2014). These adverse effects necessitate careful patient selection and monitoring.

Long-term safety data are sparse, and the impact of chronic NGF inhibition on nerve function and repair is not fully understood (Norman et al., 2016). Additionally, the optimal dosing regimen and duration of therapy in CKD patients remain undefined. The veterinary study by Nutthawat et al. (2025) provides important proof-of-concept but cannot substitute for human trials.

Cost and accessibility of anti-NGF monoclonal antibodies may also limit widespread adoption in routine nephrology practice until more evidence and regulatory approvals are established.

How this may change practice

If ongoing and future clinical trials confirm efficacy and safety, anti-NGF therapies could become a valuable option for managing chronic musculoskeletal pain in CKD patients, especially those who cannot tolerate NSAIDs or opioids. This would represent a paradigm shift toward targeted biologic pain management in nephrology, potentially improving quality of life and reducing analgesic-related renal complications.

Nephrologists should remain aware of emerging data and consider multidisciplinary collaboration with pain specialists when evaluating patients with refractory CKD-associated pain. Until more robust human data are available, anti-NGF therapy use should be confined to clinical trials or carefully selected cases with close monitoring.


References

  1. Permtorsak Nutthawat, et al. Clinical Efficacy of Anti-Nerve Growth Factor Monoclonal Antibody in Chronic Pain Management in Felines with Osteoarthritis Concurrent with Chronic Kidney Disease.
  2. Cohen SP, et al. Anti-nerve growth factor in pain management: current evidence. Journal of Pain Research 2016;9:373-383. DOI:10.2147/jpr.s89061
  3. Norman BH, et al. Targeting the Nerve Growth Factor (NGF) Pathway in Drug Discovery. Potential Applications to New Therapies for Chronic Pain. Journal of Medicinal Chemistry 2016;59(10):4385-4401. DOI:10.1021/acs.jmedchem.6b00964
  4. Schmelz M, et al. MECHANISMS OF NSAID, COX2I, AND A NEW CLASS OF DRUGS, NERVE-GROWTH-FACTOR ANTIBODY (NGF-AB), IN THE TREATMENT OF CHRONIC PAIN. 2017. DOI:10.26226/morressier.598b05d9d462b80290b5387a
  5. Bannwarth B, et al. Targeting Nerve Growth Factor (NGF) for Pain Management: What Does the Future Hold for NGF Antagonists? Drugs 2014;74(3):273-283. DOI:10.1007/s40265-014-0208-6
  6. Mizumura K, et al. Musculoskeletal pain and nerve growth factor (NGF). PAIN RESEARCH 2022;37:123. DOI:10.11154/pain.37.123

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team